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Therapeutic immunoglobulin (IG) is a purified preparation of normal human polyclonal IG derived from pooled donor plasma. It is used for treating immunodeficiency and autoimmune diseases.\[[@ref1][@ref2]\] In many of these conditions, long-term administration of IG is needed. Primarily because of the laborious processes required for purification of IG from plasma, treatment is costly, particularly for chronic conditions. Depending on the dose, infusion time, the length of treatment, and site of care, the estimated annual cost of IG therapy can ranges from \$30,000 to \$90,000 per patient.\[[@ref2][@ref3]\]

The main administration routes for IG therapy are intravenous (IVIG) and subcutaneous IG (SCIG).\[[@ref4]\] IVIG therapy has been available for decades and its use is well established in multiple disease states. SCIG has been approved for the use in the United States since 2006 and provides an alternative for patients with difficult vascular access and intolerable side effects when using IVIG or for patients desiring more independence and convenience in their therapy.\[[@ref5]\] SCIG is usually given every 1--2 weeks,\[[@ref6]\] and can be self-administered by patients after initial training by health-care professionals.\[[@ref1]\]

Serious bacterial infections (SBIs) and overall infections have been the primary and secondary phase III clinical study end-points of SCIG therapy, respectively.\[[@ref7][@ref8]\] Adverse events (AEs) associated with IG administration are recorded in clinical trials and broader clinical experience (often as text notes in physician records or clinical program data) and include local and systemic reactions. Local infusion site-related AEs, such as swelling, erythema, bruising, and pain, are more common among patients receiving SCIG as opposed to IVIG.\[[@ref9][@ref10]\]

SCIG provides increased yet consistent serum IgG levels throughout an infusion cycle and is equally efficacious to IVIG therapy in IgG replacement therapy for primary immunodeficiency (PID).\[[@ref8]\] In a multicenter, open-label, crossover randomization study, 40 patients with PID were randomly assigned to either SCIG or IVIG replacement therapy for 1 year and then switched to the alternative treatment groups in the year 2 to serve as their own controls. No significant difference in the number of infections, the severity of infections, or adverse reaction rates was noted between IVIG and SCIG therapies when receiving equivalent doses.\[[@ref8]\]

Despite the efficacy of IG therapy, patients receiving treatment can still experience disease-related complications. One of the major PID disorders treated with IG is a common variable immune deficiency (CVID). CVID patients experience several disease-related complications such as infections, primarily pneumonia, sinusitis, and otitis, although such complications should be reduced by IG treatment.\[[@ref11]\] However, other conditions such as chronic lung disease, autoimmunity, non-Hodgkin\'s lymphoma, and other cancers may or may not be modified by IG therapy. Immunodeficiency patients, in particular, may paradoxically develop autoimmunity, due to their dysregulated immune system. In one of the original CVID cohort studies, 22% of patients developed at least one autoimmune condition, such as idiopathic thrombocytopenic purpura or rheumatoid arthritis.\[[@ref12]\]

Several studies have examined the cost outcomes of SCIG therapy.\[[@ref13][@ref14][@ref15][@ref16][@ref17]\] In a 2016 study conducted by Perraudin *et al*. in Switzerland,\[[@ref16]\] the annual mean total health-care costs of home-based SCIG ranged from \$30,929 to \$ \$36,095. A 1-year Italian study conducted by Lazzaro *et al*. in 2013 found medication cost accounted for 94% of the overall \$76,778 in costs for SCIG therapy.\[[@ref15]\] Similarly, the medication was found to be the main cost driver in an Iranian study by Sadeghi *et al*. in 2015 and a German study by Hogy *et al*. in 2005.\[[@ref14][@ref17]\] Few studies were conducted in the United States, and none was found to evaluate both costs and clinical outcomes.

Based on evidence from other disease states with high health-care costs and the potential for AEs, the patient management programs have been shown to improve the patient outcomes.\[[@ref18]\] Over the past few years, a home infusion specialty pharmacy provider in the United States implemented a "high-touch" SCIG clinical management program, which includes patient training provided in the home by an IG-specialized registered nurse (RN), ongoing clinical management of infusions, AEs, and dosing, as well as disease-specific patient education. Clinical management components and disease-specific patient-reported outcomes are provided in a patient level report for the treating physician. The care team regularly communicated with the physicians about the issues identified in the clinical management process and provided timely interventions with the goals of improving clinical and cost outcomes for the patients.

This study may be the first in the United States to examine the effectiveness of a high-touch IG clinical management program on the cost and clinical outcomes of SCIG patients. Our research objective was to assess AEs, infection rates, and health-care costs for patients in this IG clinical management model compared to the matched controls.
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This retrospective cohort study compared clinical and cost outcomes of SCIG patients who were managed by an IG clinical management program to those who were not in the program using an administrative claim database in the United States from September 1, 2011, to June 30, 2014.

The IG clinical management model is standard of care for all IG patients at a national home infusion specialty pharmacy, and includes: (1) Pre-infusion clinical evaluation by a pharmacist, including evaluation for comorbidities affecting the risk of adverse drug reaction (ADR), coordination with prescribing clinician for individualized infusion plan to avoid ADR, and educating the patient to proactively address concerns; (2) Self-infusion instruction by an RN in the patient\'s home until the patient is determined to be independent by RN; and (3) Pharmacist regular clinical follow-up with the patient that is communicated to the prescribing clinician, including patient adherence, AE reporting and management, dose recommendations, and disease-specific patient-reported outcome measures. Clinical follow-up is performed over the phone by the pharmacist, that occurred every 30--60 days and on an as-needed basis to address any AEs, and also depends on patient availability. This program also facilitated patient insurance authorization and provided financial consultation.

This study was conducted using data from the PharMetrics Plus™ database (PMTX+) to derive dependent outcomes and covariates for both intervention and control cohorts. As previously described by Akinbosoye *et al*.,\[[@ref19]\] this large longitudinal database is comprised of adjudicated medical and pharmacy claims for ≥150 million unique, commercially-insured members across the United States since 2006.

For both intervention and control cohorts, the inclusion criteria were patients who received at least one claim (prescription or administration procedure) for SCIG therapy between September 1, 2011, and June 30, 2013, had continuous eligibility in the PMTX + database for a minimum 6 months before and 12 months after the index date (i.e., the date a patient received the first SCIG therapy in the study period), had at least four SCIG claims in the 12-month post-index period and one claim of SCIG on or after month 6. Similarly, both intervention and control cohorts excluded patients who were administered IVIG during the follow-up period (including the index date), had incomplete or invalid data, were prescribed products that can be administered through both SC and IV (i.e., Gammagard Liquid™; Gamunex-C™; and Gammaked™), or had a IVIG Current Procedural Terminology (CPT) or J code or a non-specific J code (J1561, J 1569) within 7 days of the National Drug Code (NDC) claim date \[[Appendix 1](#A1){ref-type="table"}\].

Data from the national home infusion specialty pharmacy were linked to the PMTX + databases to identify the intervention group, which was made up of the patients in the high-touch IG clinical management program. The program was administered across multiple locations in the United States. We used a census of all 158 patients at the national home infusion specialty pharmacy who received the services from the high-touch IG clinical management program, met the inclusion criteria, had the data in the PMTX + database were eligible for the control group \[[Appendix 1](#A1){ref-type="table"}\].

Patients in the cohorts were stratified by their autoimmune disease status, and then propensity matched on six demographic, clinical, and cost characteristics. Autoimmune disease status was categorized as: (a) IVIG-treatable autoimmune disease, (b) non-IVIG-treatable autoimmune diseases, or (c) non-autoimmune disease, using a set of the International Classification of Diseases (ICD)-9 codes \[[Appendix 2](#A2){ref-type="table"}\]. Within each autoimmune disease status category, the control group was selected from patients who were not in the program and matched 1:4 using greedy propensity score match without replacement in the PMTX + database.\[[@ref20]\] The propensity scores were obtained by regressing the following covariates into a logistic model: age at index date, gender, patient\'s proximity to 102 IG treatment centers (the list of treatment centers is not included due to space limitation), four geographic regions, Charlson Comorbidity Index score,\[[@ref21]\] and 6-month pre-index total health-care costs \[[Table 1](#T1){ref-type="table"}\]. The covariates were selected based on the interests of outcome variables through literation review and clinical judgment of our internal and external clinical experts. Propensity matching was selected because some of our outcomes were rare (SBI and serious AEs).

###### 

Baseline Characteristics of Study Population before and after Propensity Score Matching

  Characteristics                                          Subcategory                           Before Propensity Score Matching   *P*                       After Propensity Score Matching   *P*                                                                                                               
  -------------------------------------------------------- ------------------------------------- ---------------------------------- ------------------------- --------------------------------- ------------------------- --------- ------------ ------------------------- ------------ ------------------------- -------
  Age, Mean (95%CI^†^)                                                                           42.3                               (37.8-46.7)               38.9                              (37.5-40.4)               0.178     38.4         (32.5-44.3)               40.7         (37.8-43.6)               0.493
  Age Group, *n* (%)                                       0-18 years                            12                                 16.4%                     191                               25.1%                     0.242     11           24.4%                     37           20.6%                     0.947
  19-30 years                                              8                                     11.0%                              63                        8.3%                                                        4         8.9%         18                        10.0%                                  
                                                           31-54 years                           27                                 37.0%                     296                               39.0%                               18           40.0%                     73           40.6%                     
                                                           55+years                              26                                 35.6%                     210                               27.6%                               12           26.7%                     52           28.9%                     
  Male, *n* (%)                                                                                  26                                 35.6%                     276                               36.3%                     0.906     18           40.0%                     57           31.7%                     0.289
  Census Region, *n* (%)                                   Northeast                             33                                 45.2%                     136                               17.9%                     \<.0001   11           24.4%                     34           18.9%                     0.745
  Midwest                                                  11                                    15.1%                              286                       37.6%                                                       11        24.4%        44                        24.4%                                  
  South                                                    27                                    37.0%                              295                       38.8%                                                       21        46.7%        97                        53.9%                                  
                                                           West                                  2                                  2.7%                      43                                5.7%                                2            4.4%                      5            2.8%                      
  Proximity to Center, *n* (%)                                                                   50                                 68.5%                     408                               53.7%                     0.015     27           60.0%                     109          61.0%                     0.946
  Autoimmune disease, *n* (%)                              IVIG treatable autoimmune             26                                 35.6%                     236                               31.9%                     0.718     16           35.6%                     64           35.6%                     1.000
  Non-IVIG treatable autoimmune                            4                                     5.5%                               55                        7.4%                                                        3         6.7%         12                        6.7%                                   
                                                           Non-autoimmune immunodeficiency^††^   43                                 58.9%                     448                               60.6%                               26           57.8%                     104          57.8%                     
  CCI^†††^scores, *n* (%)                                  0                                     18                                 24.7%                     269                               35.4%                     0.166     14           31.1%                     52           28.9%                     0.494
  1-2                                                      38                                    52.1%                              372                       49.0%                                                       24        53.3%        90                        50.0%                                  
  3-4                                                      13                                    17.8%                              84                        11.1%                                                       7         15.6%        29                        16.1%                                  
                                                           5+                                    4                                  5.5%                      35                                4.6%                                0            0.0%                      9            5.0%                      
  Six-month, pre-index total costs, Mean^\$^ (95% CI^†^)                                         ^\$^30,559                         (^\$^22,867-^\$^38,251)   ^\$^31,752                        (^\$^29,539-^\$^33,964)   0.756     ^\$^25,422   (^\$^20,197-^\$^30,647)   ^\$^34,854   (^\$^29,489-^\$^40,218)   0.093
  Categorical costs, *n* (%)                               \<=^\$^15,000                         23                                 31.5%                     229                               30.1%                     0.995     16           35.6%                     44           24.4%                     0.351
  \>^\$^15,000, \<=^\$^30,000                              21                                    28.8%                              228                       30.0%                                                       13        28.9%        61                        33.9%                                  
  \>\$30,000, \<=^\$^60,000                                21                                    28.8%                              219                       28.8%                                                       13        28.9%        51                        28.3%                                  
                                                           \>^\$^60,000                          8                                  11.0%                     84                                11.1%                               3            6.7%                      24           13.3%                     

^†^CI=Confidence Interval; ^††^Including common variable immune deficiency; ^†††^CCI=Charlson Comorbidity Index

Infection- and infusion-related AE rates \[[Appendix 2](#A2){ref-type="table"}\] were evaluated as both the proportion of patients experiencing events of interest as well as numbers of events per patient per year as a primary clinical outcomes. All patients were followed for a 1-year postindex date to identify infections or AEs. Infections were considered in three categories: SBIs, other infections, and all infections (including both SBIs and other infections).\[[@ref7][@ref8][@ref22]\] Infusion-related AEs were categorized as serious AEs and mild less common AEs. These categories were created based on the severity and frequency of the AEs \[[Appendix 3](#A3){ref-type="table"}\].

The primary cost outcome was direct medical costs per person over the 12-month post-index period, which was defined as the amount the health plan allowed for a particular service and includes the plan paid amount plus any member liability (e.g., co-payment, deductible, and co-insurance). For calculations, the denominator included all patients in the cohort whether they experienced utilization in a service category or not. Total health-care costs were reported along with inpatient, emergency care center (EC), and outpatient costs. These costs were adjusted to 2014 prices using the Medical Care component of the US Consumer Price Index for All Urban Consumers for inflation. The following categories of direct medical costs were included: total allowable costs (calculated based on NDC, Healthcare Common Procedure Coding System (HCPCS) or CPT codes; both total IG-related and non-IG-related allowable costs were considered), total inpatient cost, total EC costs, and total outpatient costs (IG drug/administration costs which were based on HCPCS/CPT codes and nonIG-related costs), and total pharmacy costs (IG drug/administration costs were calculated based on NDC codes). Annual in-patient and out-patient costs for patients were considered to be outliers if they were at or above five times the standard deviation and were capped at five times the standard deviation, based on the distribution.

Chi-square or Fisher\'s exact test for categorical variables and Student\'s t-test for continuous variables were used to compare differences in baseline characteristics between groups. For categorical measures, frequency and percentage of total patients observed in each category were reported. For continuous variables, the mean and confidence interval were presented.

Because some national home infusion specialty pharmacy sites modified the program during the 3-year-study period, we adjusted both clinical and cost outcomes for these site-specific differences for intervention group when possible. These sites were not dropped from the analysis to prevent further reduction in the study sample. The AE and infection rates used general estimating equation (GEE) models with a log link, negative binomial distribution to adjust for site differences. GEE models were selected to account for the within-subject correlation of the matched cases and controls. Chi-square or Fisher\'s exact test was used to compare the proportion of AEs and infections between groups. Unadjusted results are presented, if the GEE model did not converge.

The mean costs after adjusting for site differences were reported and compared between intervention and control groups using GEE models with a log link and gamma distribution.

P \< 0.05 was considered statistically significant. *P* value was reported as NA if the model did not converge. All data analyses were performed at a patient level using SAS 9.2 (SAS Institute INC., Cary, NC, USA).
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Baseline characteristics and clinical and cost outcomes were analyzed and compared between patients in the high-touch SCIG clinical management model and their propensity-matched controls.

After applying the inclusion and exclusion criteria, there were 73 eligible patients in our intervention group and 760 in the control group \[[Appendix 1](#A1){ref-type="table"}\]. While no significant differences were observed for age and gender between the two groups, the differences in their accessibility to an expert treatment center, geographic distribution, and autoimmune disease status were significant \[[Table 1](#T1){ref-type="table"}\]. After propensity score matching, there were 45 and 180 patients remaining in the intervention and control group, respectively, and their baseline characteristics were well balanced \[[Table 1](#T1){ref-type="table"}\].

The majority of the AEs and infection outcomes were not significantly different between the study and control groups \[P \> 0.05; [Table 2](#T2){ref-type="table"}\]. Interestingly, the proportion of patients who had a mild less common AE was significantly higher among patients in this IG clinical management program (4.4% vs. 0.0%; *P* = 0.04), suggesting greater recognition or capture of these events.

###### 

Infection rate and adverse event rate of comparison groups

  Clinical Outcomes               Mean Rate (events/patient/year, 95%CI^††^)   *P*                  Proportion of Patients (% of patients)   *P*                        
  ------------------------------- -------------------------------------------- -------------------- ---------------------------------------- ------------ ------------- ------
  Infections                                                                                                                                                            
   All Infections                 3.13 †(1.73,4.54)                            3.28 † (2.16,4.40)   0.5                                      30 (66.7%)   126 (70.0%)   0.67
   Serious Bacterial Infections   0.02 (-0.02,0.07)                            0.15 (-0.03,0.33)    NA                                       1 (2.2%)     7 (3.9%)      1.00
   Other Infections               3.11† (1.70,4.52)                            3.16 †(2.05,4.26)    0.5                                      30 (66.7%)   125 (69.4%)   0.72
  Adverse Events (AE)                                                                                                                                                   
   Serious AE                     0.11 (-0.02,0.24)                            1.31 (-0.10,2.71)    NA                                       3 (6.7%)     22 (12.2%)    0.29
   Mild Less Common AE            0.09 (-0.04,0.21)                            0 (NA)               NA                                       2 (4.4%)     0 (0.0%)      0.04

^†^The means after adjustment of site differences by regression model are also available for "All Infections" and "Other Infections" rates. For "All Infections," the regression-adjusted rates are 3.46 and 4.40, respectively, for the intervention and control groups. For "Other Infections," the regression-adjusted rates are 3.41 and 4.25, respectively, for the intervention and control groups; ^††^CI=confidence internal

Significantly lower costs were observed for patients who received care as a part of IG clinical management program \[[Table 3](#T3){ref-type="table"}\] compared to matched controls. The annual mean total allowable cost of patients in the program was \$20,868 lower (24% lower) compared to matched controls (*P* = 0.009). Costs were also significantly lower for total inpatient and outpatient services: \$7,949 (*P* = 0.03) and \$21,317 (*P* = 0.003) lower among patients with IG clinical management program, respectively. Although not statistically significant, total EC and pharmacy costs were also lower by \$122 (*P* = 0.435) and \$7,810 (*P* = 0.398). Total IG-related costs were \$10,586 lower in the IG Clinical Management Program group; IG-related outpatient costs were \$23,409 lower. While total pharmacy cost was lower in the intervention group, the IG-related pharmacy cost was higher; however, this difference was not statistically significant (*P* = 0.522).

###### 

Regression-adjusted total allowable cost of comparison groups

  Total Allowable costs†   Intervention (*n*=45) \[A\] Mean (95%CI††),\$   Control (*n*=180) \[B\] Mean (95%CI††),\$   *P*      Mean difference, \$\[A\]-\[B\]             
  ------------------------ ----------------------------------------------- ------------------------------------------- -------- -------------------------------- --------- --------
  Total Costs              66,450                                          (55,353, 79,772)                            87,318   (71,121, 107,205)                0.009     20,868
  IG-related               48,248                                          (40,026, 58,157)                            58,834   (46,741, 74,056)                 0.168     10,586
  Total Inpatient Costs    3,398                                           (1,462, 7,898)                              11,347   (4,212, 30,566)                  0.03      7,949
  Total EC Costs^†††^      222                                             (90, 545)                                   344      (122, 974)                       0.435     122
  Total Outpatient Costs   28,008                                          (22,164, 35,394)                            49,325   (37,341, 65,154)                 \<0.001   21,317
  IG-related               16,650                                          (11,809, 23,475)                            40,059   (26,281, 61,060)                 0.001     23,409
  Total Pharmacy Costs     26,543                                          (17,623, 39,979)                            34,353   (20,794, 56,753)                 0.398     7,810
  IG-related               27,887                                          (18,036, 43,121)                            23,507   (13,732, 40,241)                 0.522     -4,380

^†^Mean costs per patient per year are means after adjustment of site differences by regression model; ^††^CI=confidence interval; ^†††^EC=emergence center
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In this study, we evaluated the clinical and cost outcomes for patients managed by a high-touch clinical management program compared with a propensity-matched control group within a national health-care claim database. Our results showed comparable clinical outcomes between the patients managed by the home setting care model and the control patients, which could be from other potential care models, such as hospital inpatient, hospital outpatient infusion center, or physician office. Therefore, this study confirms others that demonstrated the safety of the administration of SCIG in the home setting.\[[@ref22][@ref23]\] The high-touch IG clinical management model relies upon strong physician--pharmacist--nurse collaborations with coordinated clinical services that include pre-infusion clinical evaluations to proactively identify risks for ADR, individualize infusion plans, identify disease-specific patient-reported outcomes measures, and education on self-infusions by RN until the patient is independent. The high-touch model aspires to provide a residual network for data reporting and communication that encourages, identifies, and rapidly responds to patient concerns.

Our results show that patients in the high-touch clinical managed group had significantly lower health-care costs across all health-care settings. The greatest cost difference was in IG-related outpatient services (\$23,409), which may indicate reduced physician office visits in the intervention group.

Many of our cost results are consistent with the published literature.\[[@ref15][@ref17][@ref24][@ref25]\] For example, our study noted IG-related costs, including drug and administration costs, were the main cost driver. Similarly, several other previously published cost studies also noted that the main cost driver was IG preparation. However, most were conducted in countries outside of the US (Canada, France, Italy, and Germany) with diverse health system models, and may not have included administration costs.\[[@ref15][@ref17][@ref24][@ref25]\] In addition, another study noted that inpatient infusion was less economical, compared to alternative sites of care, in part due to benefit design.\[[@ref26]\] Benefit design may have played a significant role in our study, depending on whether the costs were charged to the medical or pharmacy benefit. Nevertheless, our findings added new information to the existing literature by showing the value of a clinical management program. A larger scale study is needed to explore further the potential reasons for these lower costs in the intervention group.

The majority of clinical outcomes studied in this analysis (i.e., infection- and infusion-related AE rates) were similar between intervention and matched controls, although the mild less common AEs were significantly higher in the high-touch group. The observed increased rate of mild less common AE may be a reporting byproduct also due to the high-touch, ongoing clinical management of the patient. This regular communication with the patient, patient education about AE monitoring, and regular communication between the home infusion and specialty pharmacy\'s pharmacists or RN with the treating physician would theoretically result in more comprehensive reporting of mild AEs. We perceive this as a benefit. Ideally, the early recognition of warning signs would be of value in matching them with appropriate clinical management and preventing their further development or progression into more severe consequences. This might partially explain the significantly lower out-patient and in-patient costs in the intervention group. While this remains a hypothesis at this point, additional research would be able to demonstrate the benefits of increased reporting, communication, and "high touch," through a prospectively designed and powered study.

The current study provided important insights into the effectiveness and efficiency of a high-touch clinical management program using propensity score matching and regression adjustment to control for confounding; however, there are several limitations in our study that must be considered. Some of these limitations are usual to most retrospective, observational studies using claims and administrative databases because administrative data sets are not designed to conduct the research. Such limitations include missing data, coding biases, and channeling bias. The populations of patients selected for one particular treatment over the other may have different characteristics leading to channeling bias. Some of these differences can be measured (age, gender) and therefore, can be controlled in this study, but others are unknown or not measurable. Furthermore, there might be the difference in the number of SGIC treatment received in the follow-up period between cases and controls. Due to the inclusion and exclusion criteria and propensity score matching process, there were only 45 patients in the intervention group. While the sample size is similar to many other SCIG studies,\[[@ref8][@ref23][@ref27][@ref28][@ref29][@ref30]\] this limits its power to detect a rare AE and generalizability of the study results. This study did not include new-to-therapy patients; hence, we could not extrapolate our findings to new SCIG users. The control group could be composed of patients who could receive care from a variety of clinical programs/models other than the one described in this study. Finally, from administrative data, we could not determine whether any patients in the matched control group received any services similar to the clinical management provided to the intervention group in this study.

A high-touch IG clinical management program was shown to be associated with lower health-care cost and comparable infection or AE rates. Our findings show that the provision of a high-touch IG care model can be employed in the United States without compromising cost or outcomes. With the US health-care system under increasing pressure to reduce health-care expenditure and improve clinical outcomes, these findings could provide support for the potential role that a high-touch SCIG clinical management program might provide. Further research would be needed to identify the type of patients that may benefit the most from high-touch models and compare results to other models.
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###### 

Study population attrition table

  Criterion                                                                                                      Intervention, *n* (%)   Control, *n* (%)
  -------------------------------------------------------------------------------------------------------------- ----------------------- ------------------
  Patients received SCIG during the 6 months preindex period (September 1, 2011,-June 30, 2013)                  158 (100.00)            1819 (100.00)
  AND met continuous enrollment in the PMTX+ database for a minimum of 6 months before the index date            109 (69.00)             1420 (78.10)
  AND met continuous enrollment criteria in the PMTX+ database for a minimum of 12 months after the index date   87 (55.10)              1011 (55.60)
  AND with at least four claims of index IG in the 12 month postindex period                                     84 (53.20)              916 (50.40)
  AND with one claim of index IG on or after month six (i.e., after day 150 from index)                          80 (50.60)              851 (46.80)
  AND without IMIG administration (exclusion criteria)                                                           80 (50.60)              851 (46.80)
  AND not receiving both SCIG and IVIG during the 12 months postindex period                                     73 (46.20)              763 (42.00)
  AND with complete data and valid data                                                                          73 (46.20)              760 (41.80)
  Patients postpropensity score 1-4 matching                                                                     45 (28.50)              180 (9.90)

IG=Immunoglobulin, SCIG=Subcutaneous IG, PMTX+=PharMetrics Plus database, IMIG=Intramuscular IG, IVIG=Intravenous IG

###### 

The classification of autoimmune disease covariate

  Disease                                                                                                                                         ICD-9-CM                     IVIG-treatable auto-immune disease   Non-IVIG-treatable auto-immune disease   Nonautoimmune disease
  ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------ ---------------------------------------- -----------------------
  CVID                                                                                                                                            279.0X                                                                                                     Yes
  Immunodeficiency diseases                                                                                                                       279.1X, 279.2, 279.3                                                                                       Yes
  Behςet's syndrome                                                                                                                               136.1                        Yes                                                                           
  Postpolio syndrome                                                                                                                              138                          Yes                                                                           
  Autoimmune cytopenia                                                                                                                            238.7                        Yes                                                                           
  Hashimoto's thyroiditis and thyroiditis with hyperthyroidism                                                                                    245.2                        Yes                                                                           
  Autoimmune diabetes mellitus                                                                                                                    250.01, 250.03               Yes                                                                           
  Autoimmune disease, not elsewhere classified                                                                                                    279.4X (Not 279.41)          Yes                                                                           
  Graft-versus-host disease                                                                                                                       279.5                        Yes                                                                           
  Hemolytic anemia, autoimmune                                                                                                                    283                          Yes                                                                           
  Autoimmune hemophilia                                                                                                                           286.52                       Yes                                                                           
  Henoch-Schӧnlein purpura                                                                                                                        287                          Yes                                                                           
  Idiopathic thrombocytopenic purpura                                                                                                             287.31                       Yes                                                                           
  Posttransfusion purpura                                                                                                                         287.41                       Yes                                                                           
  Autoimmune neutropenia                                                                                                                          288.09                       Yes                                                                           
  Macrophage activation syndrome                                                                                                                  288.4                        Yes                                                                           
  Acute disseminated encephalomyelitis, autoimmune encelopathy, limbic encephalitis, Rasmussen's syndrome, demyelinative brainstem encephalitis   323.81                       Yes                                                                           
  Alzheimer's disease                                                                                                                             331                          Yes                                                                           
  Stiff man syndrome                                                                                                                              333.91                       Yes                                                                           
  Cerebellar ataxia, opsoclonus-myoclonus syndrome, postinfectious, paraneoplastic cerebellar degeneration                                        334.2, 334.3                 Yes                                                                           
  Paraproteinemic neuropathy                                                                                                                      337.00, 337.09, 356.8        Yes                                                                           
  IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy                                                            337.1                        Yes                                                                           
  Multiple sclerosis, relapsing-remitting                                                                                                         340                          Yes                                                                           
  Epilepsy, intractable childhood                                                                                                                 345.61                       Yes                                                                           
  Narcolepsy with cataplexy                                                                                                                       347.01                       Yes                                                                           
  Lumbosacral or brachial plexitis                                                                                                                353.0, 353.1                 Yes                                                                           
  Chronic demyelinating polyneuropathy                                                                                                            356.4                        Yes                                                                           
  Guillain-Barre' Syndrome                                                                                                                        357                          Yes                                                                           
  Multifocal motor neuropathy                                                                                                                     357.89                       Yes                                                                           
  Myasthenia gravis                                                                                                                               358                          Yes                                                                           
  Lambert-Eaton myasthenic syndrome                                                                                                               358.3                        Yes                                                                           
  Necrotizing autoimmune myopathy                                                                                                                 359.81                       Yes                                                                           
  Uveitis, autoimmune                                                                                                                             360.19                       Yes                                                                           
  Grave's ophthalmopathy (thyrotoxic exophthalmos)                                                                                                376.21                       Yes                                                                           
  Autoimmune optic neuropathy                                                                                                                     377.49, 377.30               Yes                                                                           
  Brown-Vialetto-Van Laere Syndrome                                                                                                               389.1                        Yes                                                                           
  Cerebral infarctions with anti-phospholipid antibodies                                                                                          434.01, 434.11, 434.91       Yes                                                                           
  Polyarteritis nodosa                                                                                                                            446                          Yes                                                                           
  Kawasaki disease                                                                                                                                446.1                        Yes                                                                           
  Thrombotic thrombocytopenic purpura                                                                                                             446.6                        Yes                                                                           
  Anti-neutrophil antibody syndrome                                                                                                               447.6                        Yes                                                                           
  Inflammatory bowel disease                                                                                                                      555.0, 555.1, 555.2, 555.9   Yes                                                                           
  Autoimmune chronic active hepatitis                                                                                                             571.42                       Yes                                                                           
  Antiphospholipid antibody syndrome in pregnancy                                                                                                 649.3                        Yes                                                                           
  Pemphigus foliaceus, pemphigus vulgaris, pemphigus, and paraneoplastic                                                                          694.4                        Yes                                                                           
  Bullous pemphigoid                                                                                                                              694.5                        Yes                                                                           
  Cicatricial pemphigoid                                                                                                                          694.6                        Yes                                                                           
  Scleromyxedema                                                                                                                                  701.8                        Yes                                                                           
  Chronic urticaria                                                                                                                               708.1, 708.8                 Yes                                                                           
  Systemic lupus                                                                                                                                  710                          Yes                                                                           
  Systemic sclerosis (scleroderma)                                                                                                                710.1                        Yes                                                                           
  Sjӧgren's syndrome (sicca syndrome)                                                                                                             710.2                        Yes                                                                           
  Dermatomyositis                                                                                                                                 710.3                        Yes                                                                           
  Polymyositis                                                                                                                                    710.4                        Yes                                                                           
  Mixed connective tissue disease                                                                                                                 710.8                        Yes                                                                           
  Unspecified diffuse connective tissue disease                                                                                                   710.9                        Yes                                                                           
  Rheumatoid arthritis, severe                                                                                                                    714                          Yes                                                                           
  Felty syndrome                                                                                                                                  714.1                        Yes                                                                           
  Juvenile idiopathic arthritis                                                                                                                   714.3                        Yes                                                                           
  Juvenile idiopathic arthritis                                                                                                                   714.31                       Yes                                                                           
  HTLV-1-associated myelopathy                                                                                                                    721.1, 721.4, 721.91         Yes                                                                           
  Acute idiopathic dysautonomia                                                                                                                   742.8                        Yes                                                                           
  Chronic bullous disease of childhood, epidermolysis bullosa acquisita                                                                           757.39                       Yes                                                                           
  Fetomaternal alloimmune thrombocytopenia                                                                                                        776.1                        Yes                                                                           
  Sarcoidosis                                                                                                                                     135                                                               Yes                                      
  Grave's disease                                                                                                                                 242                                                               Yes                                      
  Addison's disease, autoimmune                                                                                                                   255.41                                                            Yes                                      
  Autoimmune polyglandular syndrome, type I                                                                                                       258.01                                                            Yes                                      
  Autoimmune polyglandular syndrome, type II                                                                                                      258.02, 258.03                                                    Yes                                      
  Pernicious anemia                                                                                                                               281                                                               Yes                                      
  Encephalomyelitis                                                                                                                               323.9                                                             Yes                                      
  Retinopathy                                                                                                                                     362.1                                                             Yes                                      
  Thromboangiitis obliterans                                                                                                                      443.1                                                             Yes                                      
  Churg-Strauss disease, Wegener's granulomatosis                                                                                                 446.4                                                             Yes                                      
  Temporal arteritis                                                                                                                              446.5                                                             Yes                                      
  Takayasu's arteritis                                                                                                                            446.7                                                             Yes                                      
  Autoimmune chronic active hepatitis                                                                                                             571.49                                                            Yes                                      
  Primary biliary sclerosis                                                                                                                       571.6                                                             Yes                                      
  Sclerosing cholangitis                                                                                                                          576.1                                                             Yes                                      
  Gluten-sensitive enteropathy                                                                                                                    579                                                               Yes                                      
  Infertility, immune mediated                                                                                                                    628.8                        \`                                   Yes                                      
  Pemphigoid gestationis                                                                                                                          646.8                                                             Yes                                      
  Dermatitis herpetiformis                                                                                                                        694.2                                                             Yes                                      
  Linear IgA disease                                                                                                                              694.8                                                             Yes                                      
  Erythema nodosum                                                                                                                                695.2                                                             Yes                                      
  Psoriasis                                                                                                                                       696.1                                                             Yes                                      
  Alopecia, autoimmune                                                                                                                            704                                                               Yes                                      
  Vitiligo                                                                                                                                        709.01                                                            Yes                                      
  Other rheumatoid arthritis with visceral or systemic involvement                                                                                714.2                                                                                                      
  Rheumatoid lung                                                                                                                                 714.81                                                                                                     
  Other specified inflammatory polyarthropathies                                                                                                  714.89                                                                                                     
  Unspecified inflammatory polyarthropathy                                                                                                        714.9                                                                                                      
  Ankylosing spondylitis                                                                                                                          720                                                                                                        

IG=Immunoglobulin, ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification, IVIG=Intravenous IG, CVID=Common variable immune deficiency, HTLV=Human T-cell leukemia-lymphoma virus

###### 

Clinical Outcomes: Infections and adverse events

  Description                                                                                                    Diagnosis                                                                ICD-9-CM
  -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------
  SBIs                                                                                                           Bacterial pneumonia                                                      482.XX
  Visceral abscess                                                                                               324.X, 478.24. 513.0, 567.22, 567.38, 572.0, 590.2                       
  Septicemia                                                                                                     995.91, 995.92, 038.XX, 790.7, 785.52                                    
  Bacterial meningitis                                                                                           320.X, 321.X, 322.X, 047.X, 003.21, 036.0                                
  Osteomyelitis/septic arthritis                                                                                 711.0X, 730.0X                                                           
  Other infections                                                                                               Conjunctivitis                                                           372.00, 372.05, 372.3, 372.03
  Acute bronchitis                                                                                               466                                                                      
  Acute otitis                                                                                                   382.0, 382.0X, 382.4, 382.9                                              
  Pyoderma/cellulitis/subcutaneous abscess                                                                       686.XX, 682.XX                                                           
  Mastoiditis                                                                                                    383.XX                                                                   
  Sinusitis                                                                                                      461.X, 473.X                                                             
  Upper respiratory infection                                                                                    465.8, 465.9                                                             
  Mild less common AE                                                                                            Fibrosis, cutaneous or subcutaneous                                      709.2
  Lipodystrophy                                                                                                  272.6                                                                    
  Serious AE                                                                                                     Anaphylaxis/anaphylactoid reaction/                                      995.0, 999.41, 999.49
  Anaphylactic shock                                                                                                                                                                      
  Pulmonary edema                                                                                                518.4                                                                    
  Embolism                                                                                                       444.X, 415.19, 445.X                                                     
  Seizure                                                                                                        345.0X, 345.1X, 345.2X, 345.3X, 345.4X, 345.5X, 345.8X, 345.9X, 780.39   
  Aseptic meningitis                                                                                             322.9                                                                    
  Transfusion-related acute lung injury                                                                          518.7                                                                    
  "Serum sickness"                                                                                               999.51, 999.59                                                           
  Acute renal failure/anuria/renal tubular necrosis/blood creatinine increased/blood urea increase               584.XX                                                                   
  Thrombotic complications                                                                                       453.9                                                                    
  Dermatitis bullous/dermatitis exfoliative/epidermal                                                            694                                                                      
  Hepatitis/acute hepatitis (noninfectious)/hepatic dysfunction/hepatic failure/hepatocellular damage/jaundice   573.3, 070.XX                                                            
  Neurodegeneration                                                                                              294.1                                                                    
  Neurological illness                                                                                           357.9 and 348.9                                                          

ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification, AE=Adverse event, SBIs=Serious bacterial infections
